Allison Swartz, serving as Executive Vice President and General Counsel for Progyny, Inc. (NASDAQ: PGNY), has formally reported the execution of stock sales totaling $45,021. These transactions were carried out on June 3 and June 4, 2026. Ms. Swartz disposed of a combined 1,798 shares of Progyny common stock during this period. The shares were sold at prices ranging between $25.02 and $25.08 per share. Specifically, on June 3, 2026, 1,199 shares were sold at $25.02 per share. The following day, June 4, 2026, saw the sale of an additional 599 shares at $25.08 per share. These specific sales were conducted under the guidelines of a Rule 10b5-1 trading plan, which Ms. Swartz established on May 13, 2025.
Concurrently with these sales, Ms. Swartz reported the disposition of 1,015 shares of common stock, valued at $25,452. These shares were withheld specifically to cover tax obligations. The withholding occurred upon the vesting of restricted stock units that were granted to her. The dispositions for tax purposes took place on June 3, 2026, involving 676 shares at $25.12 per share, and on June 4, 2026, involving 339 shares at $24.99 per share.
Following the completion of these transactions, Ms. Swartz directly holds 82,378 shares of Progyny common stock. The stock trading activity occurs while Progyny trades near $25.86. Over the past year, the stock has delivered a 19% return. According to analysis from InvestingPro, the company appears undervalued at current levels and maintains a balance sheet with more cash than debt. InvestingPro provides 12 additional exclusive tips for PGNY investors.
In broader corporate developments, Progyny Inc. recently reported first-quarter earnings that surpassed Wall Street expectations. The company announced adjusted earnings per share of $0.50. This figure exceeded the analyst estimate of $0.26. Revenue reached a record $328.5 million, which was slightly above the consensus estimate of $326.57 million. Excluding a large client that did not renew in 2025, revenue showed a 12.2% increase compared to the previous year.
Additionally, Progyny’s Board of Directors has authorized a share repurchase program. This program allows the company to buy back up to $200 million of its common stock. The repurchase program will be funded through available cash balances. In terms of analyst activity, Canaccord Genuity upgraded Progyny’s stock rating to Buy from Hold. The firm cited the company’s consistent streak of beating quarterly revenue and adjusted EBITDA estimates. Canaccord Genuity also raised its price target to $30 from $19.
Similarly, Citizens increased its price target for Progyny to $31 from $30. Citizens maintained a Market Outperform rating due to a higher EBITDA outlook for 2026. These developments reflect a positive sentiment among analysts regarding Progyny’s financial performance and future prospects. The stock is currently priced at 25.86, showing a change of +0.38 (+1.49%) at close. After hours trading shows a price of 25.86 with a change of 0.00 (0.00%).
Progyny is included in AI-picked strategies. ProPicks AI evaluates PGNY alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%).